Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Neurocrine Biosciences鈥� SEC disclosures can feel like a clinical trial in itself鈥攈undreds of pages of neurology jargon, R&D cost tables, and patent-expiry timelines bury crucial signals such as INGREZZA revenue momentum and cash runway for its congenital adrenal hyperplasia program. If you have ever asked, 鈥淲here can I find Neurocrine Biosciences鈥� quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I track NBIX insider trading Form 4 transactions in real time?鈥�, you know the challenge.
Stock Titan鈥檚 AI does the heavy lifting. Our engine reads every new 10-K, 10-Q, 8-K, proxy and S-8 the moment it lands on EDGAR, then translates complex language into clear takeaways. Instead of combing through footnotes, you receive concise explanations, cash-flow highlights, and instant alerts on Neurocrine Biosciences Form 4 insider transactions real-time. Key documents and what you鈥檒l learn are grouped for fast access:
- Annual report 10-K simplified 鈥� spot INGREZZA sales trends, R&D tax credits and patent life in minutes.
- Quarterly earnings report 10-Q filing 鈥� compare sequential revenue, trial spend and liquidity ratios without crunching spreadsheets.
- 8-K material events explained 鈥� understand clinical-trial readouts or FDA updates as soon as they post.
- Executive stock transactions Form 4 鈥� monitor buying or selling that may signal management鈥檚 conviction.
- Proxy statement executive compensation 鈥� review incentive structures tied to pipeline milestones.
Whether you need understanding Neurocrine Biosciences SEC documents with AI before the market opens or a deeper dive into NBIX earnings report filing analysis for strategy meetings, Stock Titan delivers complete, continuously updated coverage鈥攏o biotech PhD required.
Dr. Kevin Charles Gorman, a director of Neurocrine Biosciences (NBIX), exercised 106,322 non-qualified stock options with an exercise price of $35.99 and sold 106,322 resulting shares on 08/07/2025. The sales were effected by a broker under a Rule 10b5-1 trading plan adopted on February 24, 2025, at a weighted-average price of $126.4111 per share (sales ranged $124.80鈥�$129.03). After the transactions, Dr. Gorman beneficially owns 514,596 shares; 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which he has voting and investment power. The options were granted on February 5, 2016, vested in monthly installments, and were due to expire on February 5, 2026. The disposition was effected pursuant to the pre-arranged 10b5-1 plan and the issuer鈥檚 policy prevents amendment of that plan after adoption.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
